Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

Brian Feagan; William Sandborn; Bosny Pierre-Louis; Christopher Fourment; Maria Abreu

doi:10.1097/01.MIB.0000442971.65229.5b

Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

Brian Feagan
, William Sandborn
, Bosny Pierre-Louis
, Christopher Fourment
, Maria Abreu

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	E7
Journal	Inflammatory Bowel Diseases
Volume	20
Issue number	2
DOIs	https://doi.org/10.1097/01.MIB.0000442971.65229.5b
State	Published - Feb 2014
Externally published	Yes

Access to Document

10.1097/01.MIB.0000442971.65229.5b

Cite this

Feagan, B., Sandborn, W., Pierre-Louis, B., Fourment, C., & Abreu, M. (2014). Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82)). Inflammatory Bowel Diseases, 20(2), E7. https://doi.org/10.1097/01.MIB.0000442971.65229.5b

@article{8e0d18160023449ba383db37ba326b07,

title = "Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))",

author = "Brian Feagan and William Sandborn and Bosny Pierre-Louis and Christopher Fourment and Maria Abreu",

year = "2014",

month = feb,

doi = "10.1097/01.MIB.0000442971.65229.5b",

language = "English",

volume = "20",

pages = "E7",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "Oxford University Press",

number = "2",

}

Feagan, B, Sandborn, W, Pierre-Louis, B, Fourment, C & Abreu, M 2014, 'Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))', Inflammatory Bowel Diseases, vol. 20, no. 2, pp. E7. https://doi.org/10.1097/01.MIB.0000442971.65229.5b

Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82)). / Feagan, Brian; Sandborn, William; Pierre-Louis, Bosny et al.
In: Inflammatory Bowel Diseases, Vol. 20, No. 2, 02.2014, p. E7.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

AU - Feagan, Brian

AU - Sandborn, William

AU - Pierre-Louis, Bosny

AU - Fourment, Christopher

AU - Abreu, Maria

PY - 2014/2

Y1 - 2014/2

UR - https://www.scopus.com/pages/publications/84893737768

U2 - 10.1097/01.MIB.0000442971.65229.5b

DO - 10.1097/01.MIB.0000442971.65229.5b

M3 - Comment/debate

AN - SCOPUS:84893737768

SN - 1078-0998

VL - 20

SP - E7

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

IS - 2

ER -